Want to see TBPH full AI Analyst Report?

Theravance Biopharma (TBPH) Earnings Dates, Call Summary & Reports

353 Followers

Earnings Data

Report Date

Aug 05, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

0.06

Last Year’s EPS

1.08

Same Quarter Last Year

Analyst Consensus

Hold

Based on 4 Analysts Ratings

Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 10, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call reflects a strong financial position with record sales and profitability for YUPELRI, significant progress in ampreloxetine's clinical trials, and upcoming milestone achievements for Trelegy. Despite minor operational challenges, the overall outlook remains positive with a focus on future growth and strategic objectives.

Company Guidance

During the Theravance Biopharma Third Quarter 2025 Conference Call, the company reported robust financial performance and progress in its strategic objectives. The third quarter saw YUPELRI achieving record net sales of $71.4 million, a 15% year-over-year increase, driven by a 6% increase in demand and improved net pricing. This positions YUPELRI to trigger a $25 million milestone from Viatris with just $54 million in sales needed in Q4. Theravance also highlighted the advancement of the pivotal Phase III Cyprus trial of ampreloxetine, targeting a data readout in early 2026, which could significantly impact the company’s valuation. The company ended the quarter with $333 million in cash and no debt, anticipating $75 million in near-term milestones. Furthermore, the strong performance of Trelegy, with $1 billion in sales for the quarter, is expected to yield a $50 million milestone in Q4 and $100 million in 2026. The company maintains a focus on financial discipline, achieving non-GAAP breakeven, and aims to leverage its robust balance sheet and strategic initiatives for long-term value creation.

YUPELRI Sales Growth

Third quarter net sales for YUPELRI increased 15% year over year to $71.4 million, driven by a 6% increase in demand and favorable net pricing.

Record Profitability and Financial Strength

Theravance achieved non-GAAP breakeven and ended the quarter with $333 million in cash and no debt. The company is on track to achieve near-term milestones totaling $75 million in the fourth quarter.

Trelegy Milestone Achievements

Trelegy sales reached $1 billion for the quarter, setting up the achievement of a $50 million milestone in 2025 and a $100 million milestone in 2026.

Ampreloxetine Phase III Progress

The pivotal Phase III Cyprus trial for ampreloxetine is on track for data readout in early 2026, with significant progress in NDA preparation. A KOL event for investors is planned to highlight its potential.

Theravance Biopharma (TBPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TBPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2026	2026 (Q2)	0.06 / -	1.08	―	―	―
May 07, 2026	2026 (Q1)	0.03 / -0.10	-0.27	62.96% (+0.17)	―	―
Mar 19, 2026	2025 (Q4)	1.09 / 1.15	-0.31	470.97% (+1.46)	―	―
Nov 10, 2025	2025 (Q3)	-0.13 / 0.07	-0.26	126.92% (+0.33)
Aug 12, 2025	2025 (Q2)	0.67 / 1.08	-0.34	417.65% (+1.42)
May 08, 2025	2025 (Q1)	-0.21 / -0.27	-0.24	-12.50% (-0.03)
Feb 26, 2025	2024 (Q4)	-0.20 / -0.31	-0.17	-82.35% (-0.14)
Nov 12, 2024	2024 (Q3)	-0.23 / -0.26	-0.17	-52.94% (-0.09)
Aug 05, 2024	2024 (Q2)	-0.21 / -0.34	-0.28	-21.43% (-0.06)
May 13, 2024	2024 (Q1)	-0.25 / -0.24	-0.35	31.43% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TBPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	$16.94	$17.02	+0.47%
Mar 19, 2026	$13.83	$14.01	+1.30%
Nov 10, 2025	$15.08	$18.50	+22.68%
Aug 12, 2025	$11.92	$12.42	+4.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theravance Biopharma (TBPH) report earnings?

Theravance Biopharma (TBPH) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).

What is Theravance Biopharma (TBPH) earnings time?

Theravance Biopharma (TBPH) earnings time is at Aug 05, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TBPH EPS forecast?

TBPH EPS forecast for the fiscal quarter 2026 (Q2) is 0.06.